CellCentric is a groundbreaking biotech company that is revolutionizing cancer treatment. Focused on developing a cutting-edge p300/CBP inhibitor, their mission is to transform the outcomes and quality of life for individuals with challenging and neglected cancer types. By leveraging their expertise in epigenetic research, CellCentric has identified multiple innovative targets and mechanisms to tackle cancer.

Their strategy centers around identifying the most promising opportunities, with a strong emphasis on biology, medicinal chemistry, and targeted patient populations. One of their breakthrough developments is the oral drug inobrodib, which has shown immense potential in early clinical and non-clinical data. As a monotherapy or in combination with standard care drugs, inobrodib has the ability to improve outcomes and the overall experience for cancer patients.

CellCentric's dedication to collaboration and patient engagement sets them apart, ensuring the most effective impact on tumors while prioritizing quality of life. Their patient-centric approach is further enhanced by the convenience of inobrodib, which can be taken at home, reducing the need for excessive hospital visits. With a strong track record of excellence, CellCentric is driving innovation in cancer treatment and making a tangible difference in the lives of patients